In the rare scenario of “PSA-negative” metastatic disease, mSHOX2 and mSEPT9 may play a role, mitigating the absence of reliable non-invasive surrogate markers for tumor burden that often lead to diagnostic delays and hinder effective management [11]. The gene discussed is KLK3; the disease is metastatic neoplasm.